••
Kintampo Health Research Centre begins Oxford-backed Lassa fever vaccine trial
•2 min read•1 source
The Kintampo Health Research Centre (KHRC) has officially launched a clinical trial for an experimental Lassa fever vaccine, marking a significant step in West Africa's public health preparedness. The trial, which commenced on October 14, focuses on the ChAdOx1 LassaJ vaccine and aims to evaluate its safety and the immune response it triggers in humans. This research initiative is a collaborative effort involving the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI).The study is set to involve up to 51 healthy adult volunteers at the Kintampo facility. Although Ghana is not currently experiencing a Lassa fever outbreak, health authorities and researchers emphasized that the trial is a proactive measure. The Director of the KHRC highlighted that the frequent movement of people across borders—particularly between Ghana and Nigeria, where Lassa fever is endemic—makes the development of an effective vaccine a regional priority. By testing the vaccine in a non-outbreak environment, researchers can focus on understanding its interaction with the human immune system under controlled conditions.Lassa fever remains a persistent threat in West Africa, often leading to high mortality rates and significant economic burdens on healthcare systems. If the ChAdOx1 LassaJ vaccine proves successful in these early stages, it could eventually provide a critical tool for reducing deaths and containing the spread of the virus across the sub-region. The trial represents part of a broader global strategy to develop vaccines for high-priority pathogens before they escalate into larger epidemics. Results from this phase will be crucial in determining the next steps for the vaccine's development and potential deployment.
